Hepatectomy

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Montag, Mai 20, 2024
Insurance, Patient, Hepatectomy, Liver disease, PMDA, Marketing, McGill University Health Centre, Colorectal cancer, KPC, Clinical trial, Neoplasm, Government, D&O, Head, Safety, Alpha Sigma Tau, Congress, Pancreatic cancer, Brain, Carcinoma, Rambam Health Care Campus, Lung cancer, Alpha, G&A, Liver cancer

JERUSALEM, May 20, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported first quarter 2024 financial results and provided a corporate update.

Key Points: 
  • Alpha Tau anticipates remaining adequately capitalized to support all of these programs over the coming years," he concluded.
  • In May, preclinical data demonstrating an abscopal immune effect in pancreatic murine tumor models was presented at ESTRO 2024 Congress in Glasgow.
  • Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone.
  • Targeting completion of patient recruitment in the ReSTART U.S. multi-center pivotal trial in recurrent cutaneous squamous cell carcinoma in H2 2024.

EQS-News: HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Mittwoch, April 10, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • "The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans," emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Donnerstag, März 14, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Gesellschaft mit beschränkter Haftung, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • “The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans,” emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases

Retrieved on: 
Mittwoch, März 1, 2023
Liver disease, Safety, Dispute board, McGill University Health Centre, Colorectal cancer, Vulva, Brain, Patient, Liver, Hepatectomy, Health Canada, Neoplasm, Pancreas, Alpha, Cancer, Alpha Sigma Tau, Lung, Dietary supplement, Medical imaging

The study is planned to be conducted at the McGill University Health Center in Montreal, Canada.

Key Points: 
  • The study is planned to be conducted at the McGill University Health Center in Montreal, Canada.
  • The trial will seek to recruit 10 patients who are eligible for a two-staged hepatectomy to resect liver metastases of colorectal cancer.
  • The study primarily aims to examine the feasibility of delivering Alpha DaRT sources into the liver metastases, as well as the safety of utilizing the Alpha DaRT sources in the liver by assessing the frequency and severity of related adverse events.
  • Alpha Tau CEO Uzi Sofer commented, “The authorization by Health Canada for this study to proceed represents an important milestone for the Company.

Tessera Therapeutics Highlights Advancements Across its Gene Writing™ and Delivery Platforms Including Proof of Concept Data in Non-Human Primates

Retrieved on: 
Montag, Januar 9, 2023
Phenylketonuria, Genome, Cell, Gene, PST, Flagship Pioneering, Therapy, Tissue, Biochemistry, AAV, Biotechnology, Health, DNA, PKU, Mutation, LNP, Conference, Stem cell, Disease, Hepatectomy, Exon, CAR, NHP, Allele, RNA transfection, Liver, Reverse transcriptase, Genetic distance, Sickle cell disease, Vaccine, Tessera

“Our preclinical studies demonstrate that we can deliver our Gene Writers to the right location, in the liver and beyond, and make therapeutic alterations to the genome.

Key Points: 
  • “Our preclinical studies demonstrate that we can deliver our Gene Writers to the right location, in the liver and beyond, and make therapeutic alterations to the genome.
  • The Company’s proprietary non-viral lipid nanoparticles (LNPs) are designed to deliver Gene Writers™ to targeted tissues, potentially enabling the application of Gene Writing™ therapies in vivo.
  • DNA Gene Writers™ are based on recombinase or transposase element biochemistry and have been engineered to integrate a therapeutically relevant payload of choice.
  • Additional data demonstrate the ability to write longer sequences and entire genes with high efficiency and specificity.

DGAP-News: HepaRegeniX appoints Elias Papatheodorou as new Chairman of the Board of Directors

Retrieved on: 
Freitag, April 1, 2022
Therapy, COO, BD, Janssen, Cornell University, Leadership, Hepatectomy, CBO, Board, Gesellschaft mit beschränkter Haftung, Liver, CEO, RNA, Memo, Industry, Regeneration, MediGene, Tribune, Patient, Ithaca College, Management

He foll0ws Dr. Graham Dixon who served as Chairman on the Board of HeparegeniX since 2017.

Key Points: 
  • He foll0ws Dr. Graham Dixon who served as Chairman on the Board of HeparegeniX since 2017.
  • "We are delighted to welcome Elias as our new chairman of the board.
  • "I am happy to join the HepaRegeniX board of directors in these exciting times with the first clinical results ahead and several assets in the pipeline," added Elias Papatheodorou, Chairman of HepaRegeniX' Board of Directors.
  • Elias Papatheodorou currently serves as an independent chairman of the board at Memo Therapeutics and as a board member at Tribune Therapeutics.

DGAP-News: HepaRegeniX to present key results on MKK4 inhibitors and their therapeutic efficacy at upcoming scientific conferences

Retrieved on: 
Donnerstag, November 4, 2021
Safety, AASLD, Research, 2021 Essex County Council election, TLM, Cirrhosis, Association, Mayo Clinic, Hepatectomy, Liver regeneration, Patient, Gesellschaft mit beschränkter Haftung, Liver disease, Volume, American Association for the Study of Liver Diseases, CEO, Clinical professor, MKK4, Oncology, Liver, American Association, Hope, Pulmonology, Doctor of Philosophy, Department, Pharmaceutical industry, Dietary supplement

This presentation will feature key results, which were generated by Prof Lars Zender and his research group in close collaboration with HepaRegeniX.

Key Points: 
  • This presentation will feature key results, which were generated by Prof Lars Zender and his research group in close collaboration with HepaRegeniX.
  • "We are excited to present new evidence for safety and efficacy of MKK4 inhibition at two leading conferences within a few days and look forward to inspiring scientific discussions around MKK4 inhibition," said Dr. Michael Lutz, CEO of HepaRegeniX.
  • "The excellent results of our studies with MKK4 inhibitors in preclinical models of acute and chronic liver diseases confirm our therapeutic rationale.
  • Details of the upcoming events:
    The Liver Meeting (TLM) of the American Association for the Study of Liver Disease (AASLD), Nov 12-15, 2021
    For further information please contact:

Verve Therapeutics Reports New Preclinical Data with VERVE-101 Demonstrating Robust, Durable and Precise Editing of the PCSK9 Gene for the Treatment of Cardiovascular Disease

Retrieved on: 
Donnerstag, September 23, 2021
Blood, Therapy, Moyamoya disease, Hepatectomy, Gene editing, Apolipoprotein, LDL, Security (finance), Hepatocyte, Private Securities Litigation Reform Act, Primate, Conference, U.S. Securities and Exchange Commission, Patient, Population, Gene, Method, Company, LDLR, Cardiovascular disease, LNP Media Group, Clinic, Risk, Liver, Male, Human, Research, ALT, Safety, Nasdaq, LNP, GLOBE, Dietary supplement, Vaccine, Risk management

CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported data from a new preclinical study in 36 non-human primates (NHPs) with its lead clinical candidate, VERVE-101, a potential single-course gene editing treatment for atherosclerotic cardiovascular disease (ASCVD). Findings from that study as well as additional studies in rodents demonstrated potent and durable lowering of blood PCSK9 protein and low-density lipoprotein cholesterol (LDL-C), with no evidence of adverse events or significant off-target editing. The data will be presented today at the TIDES USA Oligonucleotide & Peptide Therapeutics Conference.

Key Points: 
  • The data will be presented today at the TIDES USA Oligonucleotide & Peptide Therapeutics Conference.
  • VERVE-101 is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia (HeFH), a potentially fatal genetic heart disease.
  • VERVE-101 is designed to inactivate the PCSK9 gene, resulting in sustained reduction in PCSK9 protein levels and increased LDLR expression, leading to lower LDL-C levels and reduced risk for ASCVD.
  • Were very encouraged by these data and look forward to advancing this potentially life-changing treatment to patients with ASCVD around the world.

GATT announces first-in-man use of 'GATT-Patch', a hemostatic sealant patch, by Radboud university medical center Nijmegen

Retrieved on: 
Donnerstag, April 29, 2021
Medical specialties, Transfusion medicine, Clinical medicine, Medicine, Antihemorrhagic, Shaving, Hemostat, Radboud University Nijmegen, Radboud University Medical Center, Bleeding, Hepatectomy, Radbod

b'NIJMEGEN, The Netherlands, April 29, 2021 /PRNewswire/ -- Hemostatic sealant solutions innovator GATT Technologies announced today the successful first-in-man of its lead product GATT-Patch, used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc).

Key Points: 
  • b'NIJMEGEN, The Netherlands, April 29, 2021 /PRNewswire/ -- Hemostatic sealant solutions innovator GATT Technologies announced today the successful first-in-man of its lead product GATT-Patch, used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc).
  • Having fast and effective solutions to manage complex bleeding is crucial to prevent complications for patients during or after surgery.
  • Hemostats and sealants are used when other methods to contain the bleeding are ineffective or insufficient.
  • Stuart Head, Chief Medical Officer of GATT, commented: "Principal investigators Professor dr. de Wilt (Radboudumc), Professor dr. Porte (University Medical Center Groningen), and Professor dr. Verhoef (Erasmus Medical Center) and their teams are a fantastic group to work with.

GATT announces first-in-man use of 'GATT-Patch', a hemostatic sealant patch, by Radboud university medical center Nijmegen

Retrieved on: 
Donnerstag, April 29, 2021
Medical specialties, Transfusion medicine, Clinical medicine, Medicine, Antihemorrhagic, Shaving, Hemostat, Radboud University Nijmegen, Radboud University Medical Center, Bleeding, Hepatectomy, Radbod

b'NIJMEGEN, The Netherlands, April 29, 2021 /PRNewswire/ -- Hemostatic sealant solutions innovator GATT Technologies announced today the successful first-in-man of its lead product GATT-Patch, used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc).

Key Points: 
  • b'NIJMEGEN, The Netherlands, April 29, 2021 /PRNewswire/ -- Hemostatic sealant solutions innovator GATT Technologies announced today the successful first-in-man of its lead product GATT-Patch, used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc).
  • Having fast and effective solutions to manage complex bleeding is crucial to prevent complications for patients during or after surgery.
  • Hemostats and sealants are used when other methods to contain the bleeding are ineffective or insufficient.
  • Stuart Head, Chief Medical Officer of GATT, commented: "Principal investigators Professor dr. de Wilt (Radboudumc), Professor dr. Porte (University Medical Center Groningen), and Professor dr. Verhoef (Erasmus Medical Center) and their teams are a fantastic group to work with.